BLMS (Bloomios) EBIT: $-36.81 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bloomios EBIT?

Bloomios BLMS EBIT is $-36.81 Mil as of Sep. 2023.

Bloomios's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-25.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-36.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bloomios's annualized ROC % for the quarter that ended in Sep. 2023 was -6.85%. Bloomios's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -6,394.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bloomios's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -111.25%.

Bloomios  (OTCPK:BLMS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bloomios's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-2.56 * ( 1 - 0% )/( (48.214 + 26.562)/ 2 )
=-2.56/37.388
=-6.85 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26.002 - 7.216 - ( 0 - max(0, 31.39 - 1.962+0))
=48.214

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.932 - 8.152 - ( 0 - max(0, 33.128 - 0.346+0))
=26.562

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Bloomios's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-102.692/( ( (2 + max(-5.916, 0)) + (1.212 + max(-8.469, 0)) )/ 2 )
=-102.692/( ( 2 + 1.212 )/ 2 )
=-102.692/1.606
=-6,394.27 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.299 + 1.661 + 0.002) - (7.216 + 0.363 + 0.299)
=-5.916

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.344 + 0 + 0.002) - (8.152 + 0.363 + 0.3)
=-8.469

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bloomios's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-36.811/33.089
=-111.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bloomios EBIT Related Terms

Bloomios EBIT Historical Data

* Premium members only.

The historical data trend for Bloomios's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bloomios EBIT Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.01 -0.02 -1.76 -12.81

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -8.11 -1.66 -1.37 -25.67

BLMS vs MJNE, ACORQ, ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bloomios EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bloomios's EV-to-EBIT falls into.


Bloomios EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-36.81 Mil mean?
Bloomios (BLMS) has a EBIT of $-36.81 Mil as of Sep. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bloomios.
Is Bloomios' EBIT too high?
Bloomios' current EBIT is $-36.81 Mil.
How does Bloomios' EBIT compare to MJNE and ACORQ?
Bloomios' EBIT of $-36.81 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bloomios. Bloomios's current EBIT is $-36.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomios stock overvalued right now?
Bloomios (BLMS) has a current EBIT of $-36.81 Mil. The current EBIT is $-36.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bloomios (BLMS), the current EBIT is $-36.81 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bloomios Business Description

Address 701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.